<DOC>
	<DOCNO>NCT00000779</DOCNO>
	<brief_summary>PRIMARY : To compare immunogenicity safety several HIV-1 derive immunogen versus control HIV-infected individual CD4 count great equal 500 cells/mm3 . SECONDARY : To determine whether significant advantage one vaccine exist . Before large clinical trial anti-HIV vaccine undertake , important determine whether significant advantage one vaccine currently offer study .</brief_summary>
	<brief_title>A Phase I Comparative Blinded Trial Several HIV-1 Derived Immunogens Infected Individuals With &gt; = 500 CD4 Cells/mm3</brief_title>
	<detailed_description>Before large clinical trial anti-HIV vaccine undertake , important determine whether significant advantage one vaccine currently offer study . Patients randomize receive one four vaccine one two placebo control . The vaccine : rgp 120/HIV-1IIIB , rgp 120/HIV-1MN , rgp 120/HIV-1SF , env 2-3 . The two control immunogens aluminum hydroxide ( alum ) BIOCINE Placebo Vaccine 2 ( MF-59 adjuvant emulsion citrate buffer ) . Patients vaccinate week 0 , 4 , 8 , 12 , 16 , 20 , 28 , 36 . If significant benefit see among vaccine patient , placebo patient may receive vaccination one immunogens produce immune response .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Shortterm nonsteroidal antiinflammatory therapy . Patients must : HIV seropositivity . CD4 count &gt; = 500 cells/mm3 . Successful establishment EBVtransformed Bcell line study entry . Consent parent guardian &lt; 18 year age . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Suspected known allergy vaccine component . Medical contraindication . Problem compliance . Concurrent Medication : Excluded : Antiretroviral therapy ( e.g. , AZT , ddI , ddC ) . Agents putative immunomodulating activity ( e.g. , interferon , steroid , hematopoietin ) . Parenteral therapy ( include SC allergy sensitization ) . Other investigational HIV drug therapy . Prior Medication : Excluded : Any prior vaccination HIV . Antiretroviral therapy ( e.g. , AZT , ddI , ddC ) within past 6 month . Agents putative immunomodulating activity ( e.g. , interferon , steroid , hematopoietin ) within past 3 month . Parenteral therapy ( include SC allergy sensitization ) within past 3 month . Other investigational HIV drug therapy within past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
</DOC>